Biotech IPO, Two Follow-On Offerings Top $350M
Swiss gene editing company Crispr Therapeutics AG raised $56 million in a Goodwin Procter LLP-guided market debut Wednesday while two public biotech firms priced follow-on offerings worth more than $295 million....To view the full article, register now.
Already a subscriber? Click here to view full article